Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases. Their lead candidate, NVG-2089, is a first-in-class immunomodulator designed to improve autoimmune dysregulation without immunosuppression. The company aims to deliver novel methods for reducing autoimmune dysregulation.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $161M
Date: 05-Dec-2024
Investors: Sanofi Ventures, Blue Owl Healthcare Opportunities, Norwest Venture Partners, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, abrdn Inc., Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, Mission BioCapital
Markets: Biotechnology, Pharmaceuticals, Immunomodulators, Autoimmune Diseases, Health Care, Therapeutics, Drug Discovery, HealthTech, Life Sciences
HQ: Redwood City, California, United States
Founded: 2021
Website: https://www.nuvigtherapeutics.com/
LinkedIn: https://www.linkedin.com/company/nuvig-therapeutics-inc
Twitter: https://twitter.com/nuvigtx
Crunchbase: https://www.crunchbase.com/organization/nuvig-therapeutics
Leave a Comment
Comments
No comments yet.